Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,525 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

NCT03808103
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo, Bacteriophage preparation
Biological
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Lutherville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

NCT02490202
View directory record Official record
Conditions
Delayed Function of Renal Transplant
Interventions
SANGUINATE, Normal Saline
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05027269
View directory record Official record
Conditions
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions
AOC 1001, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 5:17 AM EDT
Recruiting Phase 2 Interventional

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

NCT06210854
View directory record Official record
Conditions
HPV Infection
Interventions
pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses)
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

NCT00824005
View directory record Official record
Conditions
Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
Interventions
Adult stem cells, Placebo
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation

NCT04651166
View directory record Official record
Conditions
Abortion, Dilation and Evacuation, Hemorrhage, Blood Loss
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
14 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Neuro Biomarkers of Smoking Behavior

NCT03811951
View directory record Official record
Conditions
Smoking Cessation
Interventions
Novolin R
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

NCT04470622
View directory record Official record
Conditions
COVID-19
Interventions
Aprepitant injectable emulsion, Saline Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Sheffield, Alabama • Orange, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

NCT00624351
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 17, 2026, 5:17 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

NCT00876902
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910845
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2Phase 3 Interventional

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

NCT04428372
View directory record Official record
Conditions
Hemodialysis Complication, Hemodynamic Instability
Interventions
Mannitol, 0.9% saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

NCT05803551
View directory record Official record
Conditions
Depression
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

The Role of Platelet Rich Plasma for Erectile Dysfunction

NCT04357353
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Platelet rich plasma, Placebo Sham Injection
Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

NCT05560477
View directory record Official record
Conditions
Meniscus Tear
Interventions
AM3101, Saline Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

NCT03814590
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted medium dose, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted high dose, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, Placebo (Saline solution)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
18
States / cities
Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

NCT03422159
View directory record Official record
Conditions
Sepsis, Severe, Septic Shock
Interventions
Ascorbic Acid, Thiamine, Hydrocortisone, Sodium Chloride 0.9%
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lakewood, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Botox in Obstructed Defecation Syndrome

NCT02160288
View directory record Official record
Conditions
Obstructed Defecation Syndrome (ODS)
Interventions
Botulinum Toxin-A, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

NCT02094586
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
3,146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
19
States / cities
Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 17, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

NCT02712788
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Milrinone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 17, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

NCT05844527
View directory record Official record
Conditions
Wound of Skin, Abdominal Wound
Interventions
MRG-001, Saline
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 17, 2026, 5:17 AM EDT